Current perspective on rituximab in rheumatic diseases.

about

Targeting B Cells and Plasma Cells in Autoimmune Diseases.Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.

P2860

Q55234556-E345AD49-B48D-44D1-A869-7C7089EFBA0C Q55283747-6FE0F3D9-9EE6-4FC9-859D-06A46B4BAF7D

P2860

Current perspective on rituximab in rheumatic diseases.

Item

http://www.wikidata.org/entity/Q42373160

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Current perspective on rituximab in rheumatic diseases.

@en

Current perspective on rituximab in rheumatic diseases.

@nl

type

Item

label

Current perspective on rituximab in rheumatic diseases.

@en

Current perspective on rituximab in rheumatic diseases.

@nl

prefLabel

Current perspective on rituximab in rheumatic diseases.

@en

Current perspective on rituximab in rheumatic diseases.

@nl

P1476

Current perspective on rituximab in rheumatic diseases.

@en

P275

Creative Commons Attribution-NonCommercial

P2860

Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis

Characterization of lymphocyte populations in nonspecific interstitial pneumonia

Rituximab Effectiveness and Safety for Treating Primary Sjögren's Syndrome (pSS): Systematic Review and Meta-Analysis

The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation

The changing landscape of biosimilars in rheumatology

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.

Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.

Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development.

P304

2891-2904

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/DDDT.S139248

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Francesca Ingegnoli

Tommaso Schioppo

P5008

ScienceSource

P577

2017-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29042750

http://www.w3.org/2001/XMLSchema#string

P921

P932

5633295

http://www.w3.org/2001/XMLSchema#string

Current perspective on rituximab in rheumatic diseases.

about

P2860

P2860

Current perspective on rituximab in rheumatic diseases.

description

name

type

label

prefLabel

P1433

P1476

P275

P2860

P304

P31

P356

P407

P478

P50

P5008

P577

P698

P921

P932

P356

P1433

P1476

P275

P2860

P304

P31

P356

P407

P478

P50

P5008

P577

P698

P921

P932